Supports

Ixekizumab Overview

Introduction of Ixekizumab

Ixekizumab is a humanized IgG4 monoclonal antibody developed by Eli Lilly & Company for the treatment of autoimmune diseases. It was designed specifically to bind interleukin-17A (IL-17A) and produced by recombinant DNA technology in a recombinant mammalian cell line. With the trade name Taltz, Ixekizumab has been successively approved for marketing in United States, European Union, Canada, Japan, and Australia, for the treatment of autoimmune diseases mainly including plaque psoriasis and psoriatic arthritis.

Mechanism of Action of Ixekizumab

The etiology of psoriasis is not fully known. But IL-17A, a proinﬂammatory cytokine produced by T helper (Th) 17 cells, plays a key role in the pathogenesis of plaque psoriasis. IL17A levels are elevated in psoriatic lesions; binding of IL17A to the IL-17 receptors on keratinocytes leads to the release of other proinﬂammatory mediators, which in turn recruit more Th17 cells, neutrophils, dendritic cells, and lymphoid cells.

By binding to IL-17A, ixekizumab inhibits its binding to the IL-17A receptor, thereby inhibiting its pro-inﬂammatory downstream effects on keratinocytes.

Fig. 1 Mechanism of Action of Ixekizumab

Clinical Projects of Ixekizumab*

NCT ID	Status	Conditions	Lead Sponsor	Update Time
NCT03485976	Recruiting	Pityriasis Rubra Pilaris	Oregon Health and Science University	April 3, 2018
NCT03099538	Recruiting	Bullous Pemphigoid, Pemphigoid	Mayo Clinic	April 4, 2017
NCT03073213	Recruiting	Psoriasis	Eli Lilly and Company	March 8, 2017
NCT03137160	Recruiting	Pyoderma Gangrenosum	Ohio State University	May 2, 2017
NCT03129100	Recruiting	Axial Spondyloarthritis	Eli Lilly and Company	April 26, 2017
NCT03073200	Recruiting	Plaque Psoriasis	Eli Lilly and Company	March 8, 2017
NCT02696798	Active, not recruiting	Spondyloarthritis	Eli Lilly and Company	March 2, 2016
NCT02757352	Recruiting	Axial Spondyloarthritis	Eli Lilly and Company	May 2, 2016
NCT03151551	Recruiting	Psoriatic Arthritis	Eli Lilly and Company	May 12, 2017
NCT02349295	Active, not recruiting	Psoriatic Arthritis	Eli Lilly and Company	January 28, 2015
NCT02584855	Active, not recruiting	Psoriatic Arthritis	Eli Lilly and Company	October 23, 2015
NCT02696785	Active, not recruiting	Spondyloarthritis	Eli Lilly and Company	March 2, 2016
NCT02634801	Active, not recruiting	Plaque Psoriasis	Eli Lilly and Company	December 18, 2015
NCT03364309	Recruiting	Plaque Psoriasis	Eli Lilly and Company	December 6, 2017
NCT01646177	Active, not recruiting	Psoriasis	Eli Lilly and Company	July 20, 2012
NCT01597245	Active, not recruiting	Psoriasis	Eli Lilly and Company	May 14, 2012
NCT01474512	Active, not recruiting	Psoriasis	Eli Lilly and Company	November 18, 2011
NCT03168347	Recruiting	Psoriasis	Wake Forest University Health Sciences	May 30, 2017
NCT03463187	Recruiting	Moderate-to-severe Chronic Plaque Psoriasis	Jiangsu HengRui Medicine Co., Ltd.	March 13, 2018

Approved Drugs of Ixekizumab**

INN (trade name)	Therapeutic area	Dosage	Strength	Route	Company	Marketing start	Market
Taltz	Plaque psoriasis, Psoriatic arthritis, Pustular Psoriasis, Erythrodermic psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Japan K.K.	March 22, 2016
Taltz	Moderate-to-severe plaque psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly & Co. Ltd.	March 22, 2016
Taltz	Active psoriatic arthritis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly & Co. Ltd.	December 1, 2017
Taltz	Plaque psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Nederland B.V.	April 25, 2016
Taltz	Psoriatic arthritis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Nederland B.V.	January 11, 2018
Taltz	Plaque psoriasis, Psoriatic arthritis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Canada Inc.	August 11, 2016
Taltz	Moderate-to-severe plaque psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Australia Pty Ltd	June 9, 2016

What We Provide

Therapeutic Antibody

Ixekizumab

We provide high-quality ixekizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Ixekizumab

** Information presented in the table were collected from the following websites:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/3999442G1
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003943/human_med_001977.jsp
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94193
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=253893

For research use only. Not intended for any clinical use.